http://www.theaustralian.news.com.au/business/story/0,28124,25625244-5005200,00.html?referrer=email&source=AusBus_Even_email_nl
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%